Table 1.
Baseline characteristics and comorbidities and anti-CD20 antibody treatment indication n (%)
| Baseline characteristics | |
| Males | 18464 (96) |
| Mean age (range, SE) | 66.6 yr (20.3-97.5, 0.0813) |
| Median, at risk (range) | 478 d (365-4083) |
| Race | |
| White | 14520 (76) |
| Black or African-American | 2460 (12) |
| Hispanic or Latino | 878 (5) |
| Native Hawaiian or Pacific Islander | 171 (1) |
| American Indian or Alaska Native | 148 (1) |
| Asian | 71 (0) |
| Missing | 1056 (5) |
| Indication for anti-CD20 antibody treatment | |
| Non-hodgkin’s lymphoma | 11384 (66.2) |
| Chronic lymphocytic leukemia | 4,110 (23.9) |
| Rheumatoid arthritis | 2,151 (12.5) |
| Wegener’s granulomatosis | 174 (1) |
| Microscopic polyangiitis | 54 (0.3) |
| Baseline comorbidities | |
| Alcohol abuse | 4286 (24.9) |
| Substance abuse | 1485 (8.6) |
| Hepatitis C | 1369 (8) |
| Cirrhosis | 808 (4.7) |
| Decompensated liver disease | 660 (3.8) |
| Hemodialysis-dependent renal failure | 597 (3.5) |
| HIV | 234 (1.4) |
| Sexually transmitted disease | 25 (0.1) |
| Total number of patients | 19304 (100) |